Onglyza

OnglyzaOnglyza (generic name Saxagliptin) was first approved for use in the United States in 2008. The product, marketed by Bristol-Myers Squibb, is an oral hypoglycemic, designed to be used by itself or in conjunction with other pharmaceutical products to treat type 2, or adult onset, diabetes.

Over the last few years, however, Saxagliptin has repeatedly been linked to a number of serious side effects, including anaphylactic shock, acute pancreatitis and upper respiratory tract infection. In 2014, the FDA launched an investigation of the health risks of the drug after receiving reports of higher than normal fatal heart attacks among users. The FDA’s investigation found that individuals who used Onglyza had a 27% higher risk of heart failure than those not using the product. In April, 2016, the FDA issued an additional warning regarding the elevated risk of heart failure for patients using Onglyza.

Onglyza users have also reported alarming rates of pancreatic and thyroid cancer. As a result, the FDA has requested warnings to appear on the drug’s label, referring to the cancer and cardiac risks.

If you or someone you love has suffered injury after taking Onglyza, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory.

    Latest Article

      GETLEGAL®ATTORNEY DIRECTORY

      Find Leading Attorneys in Your Area

          NEED PROFESSIONAL HELP?

          Talk to an Attorney

          How It Works

          • Briefly tell us about your case
          • Provide your contact information
          • Choose attorneys to contact you

          About GetLegal

          Our mission at GetLegal is to develop a family of sites that constitute the most useful, informative, reliable and exciting collection of legal resources on the web. We are constantly working to expand and improve many resources we offer to legal professionals and the public.

          List Your Law Firm in the GetLegal Attorney Directory
          Advertise With Us
          Newsletter Sign-Up

          By submitting information to this site, you give permission to GetLegal, or a partner of GetLegal, to contact you by email.

          © 2008-2022 LawConnect, Inc. All rights reserved. Sitemap | Copyright/DMCA Policy | Privacy Policy | Terms of Use | Disclosures/Disclaimers